Anji Miller, MSc PhD is a highly accomplished Innovation Professional with over 20 years’ experience of translating early-stage academic research in the Life Science sector. She has extensive experience of IP related transactions and management, including, licensing, strategic partnership, funding, business development of healthcare technologies and development of knowledge transfer policies.

 As a proponent for professional advancement in technology transfer, Anji uses her experience in translational research, intellectual property protection, management, licensing, and company formation to train and empower emerging innovation professionals. At LifeArc she leads LifeArc’s global support of translational education, training and skills, with responsibility as the Programme Director of LifeArc’s Translational Skills Fellowship programmes, and the Lead for advancing the Innovation Hubs for Gene Therapies’ gene therapy skills agenda. She also holds management responsibility for specific projects within LifeArc’s translational portfolio.

An advocate of equity diversity and Inclusion (EDI), Anji is a cofounder of Global Equality, Diversity, and Inclusion in Technology Transfer (GEDITT), an initiative with a mission to raise awareness and promote EDI in the technology transfer sector. She also works closely with industry, academia, and associations to implement ED&I strategies and policies, and is an active participant in LifeArc’s policy engagement.

Anji earned an M.Sc. in Human Molecular Genetics and Ph.D. in Cancer Genetics from Imperial College, as well as an M.Sc. and Certificate in Intellectual Property Law from Queen Mary, University of London. She is a certified project manager (PRINCE2) and is both a Registered Technology Transfer Professional (RTTP) and a Certified Licensing Professional (CLP).

A seasoned tech transfer professional, Anji holds numerous advisory roles and is a Board Director of AUTM, ASTP, ATTP, and CLP. She is also the Chair of the Licensing Executive Society International (LESI) Life Science Committee, and a member of the BioIndustry Association Cell & Gene Therapy Advisory Committee.